NCT04387682

Myeloid-derived Suppressor Cells (MDSCs) in OSCC Patients

Status unknown NA Last updated 14 May 2020

What this trial tests

NA trial testing β-glucan in Squamous Cell Carcinoma of the Oral Cavity in 130 participants. Status unknown.

Timeline

22 March 2017

Primary endpoint
31 December 2019

21 March 2021

Quick facts

Lead sponsor	National Taiwan University Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	sequential
Masking	single
Primary purpose	prevention
Enrollment	130
Start date	22 March 2017
Primary completion	31 December 2019
Estimated completion	21 March 2021
Sites	1 location across Taiwan

Drugs / interventions tested

• β-glucan

Conditions studied

• Squamous Cell Carcinoma of the Oral Cavity — all drugs for Squamous Cell Carcinoma of the Oral Cavity →

Sponsor

National Taiwan University Hospital

Who can join

Adults 20 to 80, any sex, with Squamous Cell Carcinoma of the Oral Cavity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Oral squamous cell carcinoma (OSCC) has the highest annual increase in the rate of death among the top 10 leading cancers in Taiwan. This research aimed to explore whether increased anti-tumor immunity for OSCCs reduces the recurrence rate or improves survival. We first identified CD33+/CD11b+/HLA-DR-/low/CD14+/- as myeloid-derived suppressor cell (MDSC) surface markers by using flow cytometry to compare the MDSC frequency of OSCCs with blood samples from healthy donors (HDs). We then re-confirmed the suppression of T cell proliferation and function achieved by co-culturing with OSCC-educated MDSCs. We subsequently explore whether using particulate β-glucan as a food-grade supplement promotes the human immune system via subversion of immune modulatory MDSCs. Lastly, we correlated clinicopathological parameters with MDSCs and β-glucan administration to examine anti-tumor immunity, and to predict the therapeutic effect and prognosis in OSCC patients..

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer.
   Li K, Shi H, Zhang B, Ou X, et al · · 2021 · cited 687× · PMID 34620838 · DOI 10.1038/s41392-021-00670-9
2. Tissue-Resident and Recruited Macrophages in Primary Tumor and Metastatic Microenvironments: Potential Targets in Cancer Therapy.
   Cotechini T, Atallah A, Grossman A. · · 2021 · cited 49× · PMID 33924237 · DOI 10.3390/cells10040960
3. Granulocytic Myeloid-Derived Suppressor Cells as Negative Regulators of Anticancer Immunity.
   Kramer ED, Abrams SI. · · 2020 · cited 42× · PMID 32983128 · DOI 10.3389/fimmu.2020.01963
4. From Cancer Therapy to Winemaking: The Molecular Structure and Applications of β-Glucans and β-1, 3-Glucanases.
   Caseiro C, Dias JNR, de Andrade Fontes CMG, Bule P. · · 2022 · cited 40× · PMID 35328577 · DOI 10.3390/ijms23063156
5. Targeting Myeloid-Derived Suppressor Cells in Ovarian Cancer.
   Mabuchi S, Sasano T, Komura N. · · 2021 · cited 33× · PMID 33562495 · DOI 10.3390/cells10020329
6. Modulation of T-cell function by myeloid-derived suppressor cells in hematological malignancies.
   Bhardwaj V, Ansell SM. · · 2023 · cited 20× · PMID 37091970 · DOI 10.3389/fcell.2023.1129343
7. Harnessing myeloid cells in cancer.
   Park SY, Pylaeva E, Bhuria V, Gambardella AR, et al · · 2025 · cited 15× · PMID 40050933 · DOI 10.1186/s12943-025-02249-2
8. Targeting pattern recognition receptors for cancer therapy: Mechanisms and strategies.
   Ouyang D, Chen R, Xie H, Yang X, et al · · 2025 · cited 1× · PMID 41311391 · DOI 10.1016/j.apsb.2025.09.007